Congressmen Brett Guthrie and Morgan Griffith have announced a second hearing in their series on health care affordability. The hearing, titled “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain,” will take place on February 11, 2026, at the Rayburn House Office Building in Washington, D.C. This event aims to explore the prescription drug supply chain’s role in health care costs.
“This marks the second hearing in our health care affordability series, confirming Republicans’ commitment to meaningfully lowering the cost of care for American families,” said Chairmen Guthrie and Griffith. They emphasized the importance of examining the entire prescription drug supply chain to identify root causes of high costs and potential solutions.
Lori M. Reilly, Chief Operating Officer of Pharmaceutical Research and Manufacturers of America (PhRMA), is scheduled to testify at the hearing. She said, “As the Subcommittee works to make health care more affordable, examining the role of the pharmaceutical supply chain, and how it affects which medicines patients can access and how much they pay, is essential to the conversation.”
PhRMA represents leading biopharmaceutical research companies focused on developing new treatments. Over a decade, PhRMA members have invested over $850 billion in research and development. In recent years, infrastructure investments by these companies have increased significantly, contributing an estimated $1.2 trillion in economic output and creating over 100,000 jobs.
The hearing will be open to both public and press attendance and will be livestreamed at energycommerce.house.gov.
